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with PD. Compared to drug treatment, however, the ex-
penditures associated with DBS-STN are increased when
only direct costs are considered over a one year horizon.
PND4
THE IMPACT OF DRUG INTERACTIONS ON 
HOSPITALIZATION RATES FOR ALZHEIMER’S 
PATIENTS TREATED WITH DONEPEZIL
Rizzo J1, Chang S2, Cohen A2
1The Ohio State University, Columbus, OH, USA; 2Novartis 
Pharmaceutical Corporation, East Hanover, NJ, USA
OBJECTIVES: to determine whether Alzheimer’s disease
patients prescribed donepezil concurrently with an inter-
acting drug will have higher hospitalization rates than
those not on donepezil.
METHODS: 1999 MEDSTAT Marketscan data was used
to obtain subject information. Of 2955 Alzheimer’s patients
included in this study, 1674 received donepezil and 1281 pa-
tients did not. Mean patient age was 79.6 years and 37.9
percent of these patients were male. Multivariable logistic re-
gression was used to isolate the impact of drug interactions
with donepezil on the propensity to incur a hospitalization.
RESULTS: Each of ten interacting drugs increased the
probability of hospitalization when taken with donepezil.
These interacting effects were particularly large for ranit-
idine, which increased hospitalization by 22%, haloperi-
dol by 18%, diltiazem by 9%, and ciprofloxacin by 9%.
These interactions raised the expected costs of hospital-
ization substantially as well.
CONCLUSION: This research strongly suggests that
drug interactions with donepezil pose significant risk for
hospitalization in Alzheimer’s patients.
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OBJECTIVE: The total cost of secondary stroke has not
been well established. The high risk of stroke recurrence,
reaching almost 50% in the first five years following pri-
mary stroke, can be substantially reduced with effective
preventive health-care programs. Thus secondary preven-
tion can produce substantial clinical benefits and eco-
nomic savings. We evaluated health-care resource use
and indirect costs in a sample population of patients after
secondary stroke.
METHODS: 2nd Neurological Department clinical data-
base was reviewed and 105 secondary stroke patients
evaluated. Life expectancy was estimated using the Kaplan-
Meier method along with a parametric hazard function
estimator. Survivors were surveyed on health-care re-
source consumption within the previous year and indirect
costs including care time at home and employment sta-
tus. Average total cost and 95% bootstrap confidence in-
tervals were calculated. This survey was aimed at evalu-
ating patient’s eventual disability with the Barthel ADL
Index. The relationship between ADL score and the total
cost of secondary stroke was determined.
RESULTS: Life expectancy for a Polish patient experi-
encing a secondary stroke was found to be 3.9 years
(95%CI: 2.25 - 5.71). Average lifetime costs for second-
ary stroke totaled 52 181 USD (95%CI: 43536–61602)
(PPP 2000). The direct costs were estimated at 24,099
USD and productivity loss due to morbidity amounted to
34.3% of the total indirect cost, while the remaining
65.7% corresponded to patient home-care costs. It was
found that the total cost decreased as ADL increased.
CONCLUSION: The costs of secondary stroke are sub-
stantial in Poland mainly due to indirect costs. Studies of
the cost of primary stroke are needed to extract the precis
cost of secondary stroke. Effective secondary prevention
can produce economic savings as a result of limiting the
burden of secondary stroke.
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OBJECTIVE: To evaluate the direct costs due to Parkin-
son’s Disease (PD) in Germany.
METHODS: Using a prospective study design we evalu-
ate the health-care utilization and health-related quality
of life of 160 patients with PD in different Hoehn and
Yahr stages (HY) over a two year period in Germany
(2000–2002). Here we present a subanalysis of consecu-
tive 34 patients (mean age: 65.2  10.5) observed for a
three-month period. Costs were derived from different
German medical economic resources and determined
from the perspective of the health care provider.
RESULTS: The mean 3-month direct costs were DM
11300. DM 10000 were costs for medical treatment and
DM 1300 for non-medical services (e.g. social services,
meals on wheels, etc.). The drug costs were the major
cost-factor with DM 8940, mainly for the use of newer
compounds like dopamine agonists and COMT-inhibi-
tors. The use of subcutaneous apomorphine in advanced
stages of the disease considerably increased the costs of
treatment (DM 6400). Hospitalization, physician care
and vindication amounted to DM 1060. Direct costs in-
creased depending on the extent of the disease (HY I:
DM 2080, HY V: DM 8840). Further cost-driving fac-
tors include the occurrence of dyskinesias and motor
fluctuations. The drug and hospitalization costs are espe-
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cially influenced by the occurrence of motor complica-
tions.
CONCLUSIONS: Similar to earlier studies (Dodel et al.,
1995), an increase in costs was calculated depending on
HY stage and the occurrence of motor complications.
Compared to the medical costs, the non-medical services
contribute only in a small proportion to the overall direct
costs. The major cost factor is the drug treatment of Par-
kinson’s disease. The greatest proportion of these costs is
for drugs introduced in the last five years.
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OBJECTIVES: To assess the costs of multiple sclerosis (MS)
from a sample of 157 French patients followed during 2
years (1 year retrospectively, 1 year prospectively) and con-
secutively included from June 1995 to December 1996.
Costs included health-care consumption, lost earnings and
payment of short-term disability benefits by Social Security.
METHODS: At the time of inclusion, the costs of MS
were assessed by retrospective interviews covering a one-
year period (health-care costs and sick leaves) or since the
last consequence of MS on work (loss of earnings). The
retrospective data concerning both the health-care con-
sumption and sick leaves were completed with prospec-
tive data collected by means of a questionnaire during the
three-months following inclusion. Loss of earnings was
discounted at 5%. Cost estimates were crossed with med-
ical data at inclusion, and econometric analyses were per-
formed to assess explanatory variables of the health-care
costs.
RESULTS: Baseline statistics were: mean age, 42.9;
women, 66%; secondary progression, 37%; primary pro-
gression, 11%; median EDSS score, 5.25. Average one-
year retrospective health-care costs (N  157) amounted
to US$7,790.38 (/ US$9,713.88), with 75.4% going
towards hospital costs and 24.6% to ambulatory costs.
Main cost items were hospital stay in the neurological
ward (29.4% of the total cost) and physiotherapy
(15.4%). Three-month prospective healthcare costs
(N101) amounted to US$1,813 (/ US$2,056), with
56.5% spent on hospital costs. Physiotherapy and drugs
were the main ambulatory cost items, accounting for
40.0% and 24.6% respectively of the total prospective
ambulatory costs.
CONCLUSION: The econometric analysis showed that the
health-care costs were positively correlated with the num-
ber of years of schooling, the number of relapses, the EDSS
score and the Kurtzke sphincter subscore at inclusion,
negatively correlated with the Kurtzke sight subscore at
inclusion, and were not affected by the form of MS.
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MS affects approximately 85,000 people in the UK, of
which 25% to 40% will be RRMS patients. Treatment
costs fall largely on the NHS, but savings on social and
personal care will accrue if dependency is deferred. Sim-
plistic treatment algorithms based on crude prevalence
data may overestimate the number of patients and cost of
treatment.
OBJECTIVE: Present a treatment algorithm providing a
more realistic estimate of the number of RRMS patients
eligible for therapy, and thereby, an improved estimate of
budget implications of prescribing.
METHODS: Published prevalence data indicate the num-
ber of patients for whom treatment is theoretically eligi-
ble is 25 to 71 per 100,000 population (mid-point 48).
However, using published literature and feedback from
expert clinicians, we show that these numbers can be re-
duced to reflect those patients who will refuse injectable
therapy, are too young (below 18), have not relapsed in
the previous two years or are non-ambulatory.
RESULTS: We present an algorithm based on glatiramer
acetate, given the published evidence of long-term efficacy
and the significantly lower price (almost 30% cheaper
than the beta interferons in the UK). Using published data
to quantify the proportions of ineligible patients, the origi-
nal target population of 48 is reduced to 23. Depending on
the proportion of these patients that receives glatiramer ac-
etate, e.g., 20%, 40%, or 60%, the budget provision per
100,000 population would be £33,250, £59,850, or
£93,100 respectively, based on direct acquisition cost of
therapy alone versus best supportive care alone.
CONCLUSION: The algorithm provides a tool for deter-
mining a more realistic estimate of the RRMS population
eligible for treatment, and the direct costs to the NHS.
Given that NHS and Social Care budgets will increas-
ingly be managed jointly, budgetary impact is mitigated if
wider benefits such as deferred dependency and ability to
continue employment are taken into account.
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